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Abstract Intracellular accumulation of anthracycline deriva-
tives was measured in a human embryonic kidney cell line (HEK)
and a resistant subline (HEK/multidrug resistance protein
(MRP1)) overexpressing MRP1 at the plasma membrane
surface. Two compounds (daunorubicin and doxorubicin) were
rejected outside the multidrug-resistant cells. On the contrary,
three compounds (4P-deoxy-4P-iodo-doxorubicin, 4-demethoxy-
daunorubicin and 3P-(3-methoxymorpholino)doxorubicin) accu-
mulated equally within sensitive HEK cells and resistant HEK/
MRP1 cells. Our main objective here was to characterize the
MRP1 conformational changes mediated by the binding of these
anthracycline derivatives and to determine whether these
conformational changes are related to MRP1-mediated drug
transport. MRP1 was reconstituted in lipid vesicles as previously
described [Manciu, L., Chang, X.B., Riordan, J.R. and
Ruysschaert, J.-M. (2000) Biochemistry 39, 13026^13033].
The reconstituted protein was shown to conserve its ATPase
and drug transport activity. Acrylamide quenching of Trp
fluorescence was used to monitor drug-dependent conformational
changes. Binding of drugs (4-demethoxy-daunorubicin and 3P-(3-
methoxymorpholino)doxorubicin) which accumulate in resistant
cells immobilizes MRP1 in a conformational state that is
insensitive to ATP binding whereas drugs rejected outside the
resistant cells (daunorubicin, doxorubicin) favor a conforma-
tional change which may be a required step in the transport
process. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Multidrug resistance (MDR) is one of the major obstacles
encountered during cancer chemotherapy. This resistance is
frequently associated with the overexpression of P-glycopro-
tein (Pgp) [1] or MDR protein 1 (MRP1) [2]. According to
their sequence, these two proteins belong to the large ATP
binding cassette (ABC) superfamily of membrane transport
proteins that includes yeast, bacteria, and mammalian trans-
porters [3]. Pgp and MRP1 function as ATP-dependent e¥ux
pumps that extrude cytotoxic drugs from cells before they can
reach their intracellular targets, thus conferring cell resistance
to many structurally and functionally unrelated anti-cancer
drugs including the Vinca alkaloids, anthracyclines, etoposide,
taxol, colchicine and actinomycin D [4^6]. Experiments with
inside-out membrane vesicles indicated that MRP1 transports
a range of substrates that are conjugated to glutathione
(GSH), glucuronide or sulfate [7^13] but also unconjugated
compounds (daunorubicin (DNR), vincristine and etoposide)
provided that GSH is also present [14^16]. The mechanism by
which MRP1 transports conjugated organic anions and un-
modi¢ed xenobiotics has yet to be elucidated. However, it is
likely that, like Pgp, MRP1 is a ATP-dependent drug e¥ux
pump and that ATP hydrolysis is coupled to drug transport.
Distinct Pgp conformations induced by drugs and ATP bind-
ing have been characterized [17^21]. Recently, puri¢ed MRP1
reconstituted into lipid vesicles has been shown to adopt dif-
ferent conformations during its catalytic cycle [22].
The aim of the present study is to characterize the nucleo-
tide-induced MRP1 conformational changes in the presence of
a series of anthracycline derivatives and to determine whether
these conformational changes are related to MRP1-mediated
drug transport.
Intracellular accumulation of DNR, doxorubicin (DOX)
and several derivatives (4P-deoxy-4P-iodo-doxorubicin (iodo-
DOX), 4-demethoxy-daunorubicin (demethoxyDNR) and 3P-
(3-methoxymorpholino)doxorubicin (FCE)) was measured by
£ow cytometry in human embryonic kidney cell line (HEK)
and its resistant, (MRP1)-overexpressing subline (HEK/
MRP1). IodoDOX, demethoxyDNR and FCE accumulated
equally into sensitive HEK cells and resistant HEK/MRP1
cells. On the contrary, accumulation of DNR and doxorubicin
was lower in resistant HEK/MRP1 cells compared to sensitive
HEK cells. Quenching of tryptophan (Trp) £uorescence by
acrylamide revealed that MRP1 adopts di¡erent conforma-
tions upon addition of MgATP and anthracycline derivatives
and that the coupling between the drug binding site and the
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catalytic cycle is di¡erently a¡ected by drugs which accumu-
late or do not accumulate in resistant cells overexpressing
MRP1.
2. Materials and methods
2.1. Materials
IodoDOX, demethoxyDNR and FCE were obtained from Pharma-
cia-Farmitalia (Milan, Italy). Daunorobucin (DNR), doxorubicin
(DOX), ATP and adenosine-5P-O-(3-thiotriphosphate) (ATPQS) were
purchased from Sigma. Hygromycin B was a Boehringer product.
Dulbecco’s modi¢ed Eagle medium (DMEM), fetal calf serum, L-glu-
tamine and penicillin-streptomycin solution were supplied by Gibco
BRL. Asolectin (Sigma) was puri¢ed according to the method of
Kagawa and Racker [23] and stored at 320‡C in chloroform.
FITC-conjugated secondary antibody was a Coulter product.
2.2. Cell lines and cell culture
The cell lines used were HEK and its drug-resistant subline HEK/
MRP1. The HEK/MRP1 cells overexpressing MRP1 were obtained
by transfection with a pCEBV7 expression vector containing the full-
length MRP1 cDNA (pCEBV7-MRP1). The parental cell line (HEK)
was transfected with pCEBV7 vector alone. The pCEBV7 vector was
derived from pREP7 expression vector by replacing the Rous sarcoma
viral promoter with a cytomegalovirus promoter. This vector contains
also the hph gene from Escherichia coli that confers resistance to
hygromycin B and allows maintenance of the vector in transfected
cells. Cells were cultured in DMEM medium supplemented with
10% fetal calf serum, 2% L-glutamine and 1% penicillin-streptomycin
solution at 37‡C in a humidi¢ed atmosphere of 5% CO2.
It has been established by £ow cytometry measurements on cells
incubated with the antiMRP1 monoclonal antibody (QCRL-1)
(kindly provided by Dr. R.G. Deeley (Queen’s University, Kingston,
ON, Canada)) coupled to a FITC-labeled secondary antibody that, in
contrast to sensitive cells, the HEK/MRP1 resistant cell line expresses
MRP1 at the membrane surface. No Pgp was detected using an
antiPgp monoclonal antibody (MRK16) (Research Diagnostics, Inc.).
2.3. Puri¢cation and reconstitution of MRP1
The puri¢cation and reconstitution of MRP1 was carried out as
described previously [22,24]. Proteoliposomes were prepared by incu-
bation of asolectin liposomes with puri¢ed protein dissolved in 0.1%
DDM. The detergent/protein/phospholipid mixture was gently stirred
for 20 min at 4‡C and the detergent was removed by adding SM2 Bio-
Beads.
2.4. Drug accumulation
Cellular accumulation of anthracycline derivatives was measured as
described [25]. Brie£y, 106 cells/ml were incubated for 3 h with 1 WM
of di¡erent anthracyclines in DMEM complete medium at 37‡C. They
were then washed twice in PBS bu¡er (containing 135 mM NaCl, 2.5
mM NaH2PO4 and 9 mM Na2HPO4) and resuspended in 500 Wl PBS.
Cell £uorescence was measured by £ow cytometry on a EPICS0-
PROFILE II cytometer. 5U103 cells were counted in each case.
Each experiment was repeated at least three times.
2.5. ATPase activity
The ATPase activity of proteoliposomes was measured according to
the procedure described by Shapiro and Ling [26]. The protein content
of the samples was determined by the method of Peterson [27].
2.6. Fluorescence quenching
Acrylamide quenching experiments were performed on a SLM
Aminco 8000 spectro£uorimeter at room temperature as describedFig. 1. Anthracycline structures.
Fig. 2. Cellular accumulation of anthracyclines. Fluorescence inten-
sity histograms were obtained by £ow cytometry after incubation of
HEK (9) and HEK/MRP1 (WWWW) cells (106 cells/ml) with di¡erent an-
thracyclines (1 WM) at 37‡C. A, DNR; B, DOX; C, iodoDOX; D,
FCE 23762; E, demethoxyDNR; F, HEK/MRP1 resistant cells
without drugs (pro¢le was the same for the sensible cells). Fluores-
cence intensity is displayed on a log scale. A total of 10 000 cells
were counted for each histogram. Experiments were repeated three
times and gave essentially the same pro¢les as the ones shown here.
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previously [22]. The excitation wavelength was set at 290 nm and
£uorescence was monitored at 334 nm. Increasing amounts of acryl-
amide were added from a 3 M stock solution to the proteoliposomes
suspension (1 ml in water) containing 7 Wg of reconstituted MRP1 and
various ligands. The ¢nal concentrations for the nucleotides and GSH
were 3 and 2.5 mM respectively. Anthracycline derivatives were added
to a ¢nal concentration of 10 WM. The acrylamide concentration was
from 0 to 0.08 M. Above this concentration, the static quenching by
acrylamide is responsible for the deviation from linearity in Stern^
Volmer plots. The quenching data were plotted according to the
Stern^Volmer equation [28]:
F0=F  1 K svQ 1
where F0 and F are the £uorescence intensities in the absence and
presence of the acrylamide, [Q] is the concentration of acrylamide,
and Ksv is the Stern^Volmer quenching constant.
3. Results
3.1. Cellular accumulation of drugs at the steady state
Cellular accumulation of several anthracyclines (Fig. 1) in
HEK and HEK/MRP1 cells was measured at the steady state
by £ow cytometry [25]. The £uorescence histograms of cells
incubated during 3 h with the anthracyclines are shown in
Fig. 2A^E. The £uorescence of cells incubated without any
drug was also recorded and the £uorescence histogram is dis-
played in Fig. 2F. Fluorescence distribution of DNR and
DOX was signi¢cantly shifted to lower values for HEK/
MRP1 cells overexpressing MRP1. This means lower intra-
cellular concentrations of these anthracyclines as compared
to sensitive HEK cells (Fig. 2A,B). In contrast, iodoDOX,
demethoxyDNR and FCE £uorescence histograms for HEK/
MRP1 resistant cells were identical to those obtained for
HEK sensitive cells (Fig. 2C^E) indicating that those drugs
accumulate at the same extent in both cell lines.
3.2. Fluorescence experiments
Fluorescence experiments were conducted in the presence of
speci¢c ligands of MRP1 in order to detect changes of acces-
sibility of MRP1 domains to the aqueous environment occur-
ring upon binding of drugs and nucleotides. Five anthracy-
cline derivatives (DNR, DOX, iodoDOX, demethoxyDNR
and FCE) (Fig. 1) were used and added at a ¢nal concentra-
tion of 10 WM to MRP1-containing proteoliposomes in the
presence of MgATP (3 mM) or MgATPQS (3 mM) in order to
discriminate between nucleotide binding and nucleotide hy-
drolysis. All experiments were carried out at 2.5 mM GSH
[14^16,29,30]. Upon co-addition of MgATP or MgATPQS and
anthracycline derivatives, the quenching e⁄ciency was quite
dependent on the nature of the substrate added.
In the presence of drugs (DNR and DOX) which do not
accumulate in resistant cells, addition of MgATP led to the
highest level of £uorescence quenching (Fig. 3) and therefore
to the highest Trp exposure to the water environment. The
fact that MgATPQS did not signi¢cantly modify this exposure,
Fig. 3. Stern^Volmer plots of MRP1 Trp quenching by acrylamide
upon co-addition of DNR, GSH and nucleotides. Addition of doxo-
rubicin to MRP1 gives identical Stern^Volmer plots (data not
shown). F is the measured £uorescence intensity and F0 is the initial
£uorescence intensity in the absence of acrylamide. b, 3 mM
MgATP; E, 10 WM anthracycline derivative and 2.5 mM GSH; P,
10 WM DNR, 2.5 mM GSH and 3 mM MgATPQS; 8, 10 WM
DNR, 2.5 mM GSH and 3 mM MgATP. The results are the means
of three experiments. The error bars represent the standard devia-
tion.
Fig. 4. Stern^Volmer plots of MRP1 Trp quenching by acrylamide
upon co-addition of demethoxyDNR, GSH and nucleotides. Addi-
tion of FCE to MRP1 gives identical Stern^Volmer plots (data not
shown). F is the measured £uorescence intensity and F0 is the initial
£uorescence intensity in the absence of acrylamide. b, 3 mM
MgATP; E, 10 WM anthracycline derivative and 2.5 mM GSH; P,
10 WM demethoxyDNR, 2.5 mM GSH and 3 mM MgATPQS; 8,
10 WM demethoxyDNR, 2.5 mM GSH and 3 mM MgATP. The re-
sults are the means of three experiments. The error bars represent
the standard deviation.
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indicates that MgATP binding is mainly responsible for these
changes in accessibility (Fig. 3).
In the presence of drugs which accumulate both in sensitive
and resistant cells, two distinct situations were observed:
1. In the presence of FCE or demethoxyDNR, addition of
MgATP or MgATPQS did not a¡ect signi¢cantly the £uo-
rescence quenching (Fig. 4).
2. In the presence of iodoDOX, addition of MgATPQS and
MgATP caused an increase in £uorescence quenching sim-
ilar to that observed for transported drugs (DNR and
DOX) (Fig. 5).
3.3. ATPase activity of MRP1
ATP was shown to be unable to modify the £uorescence of
Trps after binding of FCE or demethoxyDNR. A possible
explanation can be that MRP1 is not able to bind and hydro-
lyze the nucleotide in the presence of these anthracycline de-
rivatives. MRP1 ATPase activity was therefore measured in
the absence and in the presence of each of the anthracycline
derivatives and GSH.
In the absence of drugs and GSH, the reconstituted MRP1
showed a basal ATPase activity of about 10 þ 2 nmol/mg/min.
This ATPase activity was 1.5^2-fold stimulated in the presence
of 20 WM anthracycline derivatives and 2.5 mM GSH (Fig. 6).
The increase in the MRP1 ATPase activity was similar in
magnitude to that reported in membrane vesicles [31].
4. Discussion
The experiments reported here demonstrate that ATP bind-
ing is necessary for the protein to undergo the conformational
change leading to the transport of DNR and DOX outside the
cell. Binding of drugs (FCE or demethoxyDNR) which accu-
mulate in the resistant cell immobilizes MRP1 in a conforma-
tional state insensitive to ATP binding and ATP hydrolysis
even though ATPase activity measurements con¢rmed that
ATP binds to MRP1 and is hydrolyzed in the presence of
the ¢ve anthracyclines tested. These observations strongly
suggest that, in the presence of drugs rejected outside resistant
cells, the protein undergoes after binding and hydrolysis of
MgATP, conformational changes which are crucial steps in-
volved in the catalytic cycle of drug transport. In contrast,
drugs like FCE and demethoxyDNR probably inhibit one
or several steps involved in the catalytic cycle. It is likely
that the structural states associated to these steps do not allow
the transport of drugs across the membrane. It has been re-
cently suggested that Lmr A, a bacterial resistance protein,
functions by an alternating two-sites mechanism [32]. Indeed,
it seems that it passes through two con¢gurations, one con-
taining a high-a⁄nity, inside-facing, drug binding site and one
containing a low-a⁄nity, outside-facing, drug release site.
Moreover, the interconversion of these two con¢gurations is
ATP-dependent. Our data suggest that non-transported drug
could be irreversibly associated to the high-a⁄nity binding
site ; addition of ATP would inhibit the conformational
change required to transport the drug to the low a⁄nity bind-
ing site and to bring the drug in contact with the water phase.
Non-transported molecules would be locked in their high
membrane a⁄nity binding site. They are not transported
and accumulate into resistant cells.
IodoDOX accumulates at the same extent in sensitive and
resistant cells although its binding to MRP1 causes the same
structural changes as those described for transported drugs. It
Fig. 5. Stern^Volmer plots of MRP1 Trp quenching by acrylamide
upon co-addition of iodoDOX, GSH and nucleotides. F is the mea-
sured £uorescence intensity and F0 is the initial £uorescence inten-
sity in the absence of acrylamide. b, 3 mM MgATP; E, 10 WM an-
thracycline derivative and 2.5 mM GSH; P, 10 WM iodoDOX, 2.5
mM GSH and 3 mM MgATPQS; 8, 10 WM iodoDOX, 2.5 mM
GSH and 3 mM MgATP. The results are the means of three experi-
ments. The error bars represent the standard deviation. Absence of
error bar means that the error bar is within the symbol.
Fig. 6. Stimulation of MRP1 ATPase activity by anthracycline de-
rivatives. ATPase activity of MRP1 was measured in the presence
of 20 WM anthracyclines and 2.5 mM GSH. Data are means þ S.D.
(n = 3). All the ATPase activity values measured in the presence of
anthracycline derivatives and GSH were statistically di¡erent from
the ATPase value of MRP1 in the absence of ligand, as calculated
with Student’s t-test (P6 0.05, n = 3).
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is likely that its high lipophilicity favors a rapid and passive
redi¡usion into the plasma membrane and its accumulation
into resistant cells overexpressing MRP1 [33].
In conclusion, we demonstrate here that the coupling be-
tween the drug binding site(s) and the catalytic sites is di¡er-
ently a¡ected by binding of anthracycline derivatives which
accumulate or do not accumulate in resistant cells. It is quite
obvious that a knowledge of the tertiary structure of the
MRP1-ligand complexes will open the way to a molecular
understanding of the resistance process associated to MRP1.
A preliminary but crucial step was to identify these structural
intermediates involved in the transport process.
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